loading
Schlusskurs vom Vortag:
$1.95
Offen:
$1.95
24-Stunden-Volumen:
544.64K
Relative Volume:
0.27
Marktkapitalisierung:
$149.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.4596
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
+16.67%
1M Leistung:
+16.67%
6M Leistung:
+100.89%
1J Leistung:
+67.65%
1-Tages-Spanne:
Value
$1.911
$2.05
1-Wochen-Bereich:
Value
$1.65
$2.05
52-Wochen-Spanne:
Value
$0.772
$2.12

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
Firmenname
Sellas Life Sciences Group Inc
Name
Telefon
(646) 200-5278
Name
Adresse
7 TIMES SQUARE, NEW YORK, NY
Name
Mitarbeiter
15
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
SLS's Discussions on Twitter

Vergleichen Sie SLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.985 149.67M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
439.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.67 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.68 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.75 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.30 28.51B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-07-21 Eingeleitet Cantor Fitzgerald Overweight
2018-11-01 Eingeleitet Oppenheimer Outperform
2018-04-02 Eingeleitet H.C. Wainwright Buy
2018-03-19 Hochstufung Maxim Group Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

pulisher
Jun 18, 2025

SELLAS Life Sciences Holds Annual Stockholders Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 16, 2025

SELLAS Life Sciences: Tons Of Completed Studies (NASDAQ:SLS) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 13, 2025

Insider Buying: VAN NOSTRAND ROBERT L Acquires Additional Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Sellas Life Sciences director Van Nostrand buys $14,800 in stock By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Sellas Life Sciences director Van Nostrand buys $14,800 in stock - Investing.com

Jun 13, 2025
pulisher
Jun 05, 2025

SELLAS adds oncology experts to advisory board By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

SELLAS Life Sciences Expands Scientific Advisory Board with - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

SELLAS Life Sciences Expands Scientific Advisory Board - citybiz

Jun 05, 2025
pulisher
Jun 05, 2025

SELLAS adds oncology experts to advisory board - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

Leading Oncology Experts Join SELLAS Advisory Board as Critical AML Trial Results Near - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Acquires 33,878 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Lif - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

SELLAS reports potential colorectal cancer therapy progress - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

SELLAS Life Sciences (SLS) Highlights Promising Results for SLS0 - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan

Jun 02, 2025
pulisher
May 26, 2025

National Bank Financial Comments on CVE:SLS FY2026 Earnings - Defense World

May 26, 2025
pulisher
May 23, 2025

Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus

May 23, 2025
pulisher
May 23, 2025

US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences Group - TipRanks

May 23, 2025
pulisher
May 20, 2025

Sellas Life Sciences Reports Improved Financial Position - TipRanks

May 20, 2025
pulisher
May 20, 2025

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times

May 20, 2025
pulisher
May 20, 2025

SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan

May 20, 2025
pulisher
May 16, 2025

Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com

May 15, 2025
pulisher
May 15, 2025

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan

May 15, 2025
pulisher
May 14, 2025

SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 14, 2025
pulisher
May 13, 2025

SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.

May 12, 2025
pulisher
May 11, 2025

SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 07, 2025

Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX

May 07, 2025
pulisher
May 02, 2025

Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX

May 02, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

May 02, 2025
pulisher
Apr 30, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Apr 29, 2025
pulisher
Apr 29, 2025

Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

SELLAS reports promising AML treatment in preclinical study - Investing.com

Apr 28, 2025

Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Sellas Life Sciences Group Inc-Aktie (SLS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Wasman Jane
Director
May 30 '25
Buy
1.69
20,000
33,800
30,400
Kalin Katherine Bach
Director
May 22 '25
Buy
1.80
20,000
36,000
41,000
$20.49
price down icon 0.05%
$35.81
price up icon 0.00%
$21.04
price up icon 1.50%
$101.02
price up icon 1.64%
$106.62
price down icon 0.15%
biotechnology ONC
$244.34
price up icon 1.30%
Kapitalisierung:     |  Volumen (24h):